• Return to Headlines

Relatively High EBITDA Growth Detected in Shares of Allergan Plc in the Pharmaceuticals Industry (AGN, ANIP, LLY, SUPN, MRK)

By David Diaz

Below are the three companies in the Pharmaceuticals industry with the highest EBITDA Growth (next year estimate vs. LTM). EBITDA Growth can be valuable in predicting future cash flow generation and earnings power.

Allergan Plc ranks highest with a EBITDA growth of 354.9%. Ani Pharmaceutic is next with a EBITDA growth of 90.3%. Eli Lilly & Co ranks third highest with a EBITDA growth of 60.9%.

Supernus Pharmac follows with a EBITDA growth of 59.4%, and Merck & Co rounds out the top five with a EBITDA growth of 58.9%.

SmarTrend recommended that its subscribers protect gains by selling shares of Ani Pharmaceutic on August 3rd, 2018 by issuing a Downtrend alert when the shares were trading at $65.96. Since that call, shares of Ani Pharmaceutic have fallen 21.9%. We are now looking for when a new Uptrend will commence and will alert SmarTrend subscribers in real time.

Keywords: highest ebitda growth allergan plc ani pharmaceutic eli lilly & co supernus pharmac Merck & Co

Ticker(s): AGN ANIP LLY SUPN MRK